Advertisement
Advertisement
TECH
Bio-Techne Corp.
72.66
USDSponsored
-0.01
-0.01%
Nov 03, 16:00 UTC -5
Closed
After-Market
72.67
+0.01
+0.01%
Bio-Techne Corp. (TECH) Earnings
TECH Earnings Reports
Positive Surprise Ratio
TECH beat 25 of 42 last estimates.
60%
Next Report
Today
Date of Next Report
Nov 03, 2026
Estimate for Q1 27 (Revenue/ EPS)
$297.20M
/$0.45
Implied change from Q2 26 (Revenue/ EPS)
-7.47%
/-2.17%
Implied change from Q1 26 (Revenue/ EPS)
+3.71%
/+7.14%
Bio-Techne Corp. earnings per share and revenue
On Aug 12, 2026, TECH reported earnings of 0.46 USD per share (EPS) for Q2 26, beating the estimate of 0.44 USD, resulting in a 3.95% surprise. Revenue reached 321.19 million, compared to an expected 320.97 million, with a 0.07% difference. The market reacted with a +0.11% price change (close before vs. close after earnings).
Looking ahead to Q1 27, -- analysts forecast an EPS of 0.45 USD, with revenue projected to reach 297.20 million USD, implying an decrease of -2.17% EPS, and decrease of -7.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Amgen Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
$5.90
Actual
$6.45
Surprise
+9.16%
Alkermes Inc. plc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.07
Actual
$0.09
Surprise
+225.00%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Mirum Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.87
Surprise
-75.30%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$2.78
Actual
-$0.78
Surprise
+72.00%
Denali Therapeutics Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.54
Actual
-$0.64
Surprise
-17.95%
Alamar Biosciences, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.19
Surprise
+12.96%
Ultragenyx Pharmaceutical Inc.
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$1.13
Actual
-$1.15
Surprise
-1.83%
Arvinas, Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.71%
FAQ
What were Bio-Techne Corp.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bio-Techne Corp. reported EPS of $0.46, beating estimates by 3.95%, and revenue of $321.19M, 0.07% above expectations.
How did the market react to Bio-Techne Corp.'s Q2 2026 earnings?
The stock price moved up 0.11%, changed from $72.15 before the earnings release to $72.23 the day after.
When is Bio-Techne Corp. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Bio-Techne Corp.'s next earnings report?
Based on --
analysts, Bio-Techne Corp. is expected to report EPS of $0.45 and revenue of $297.20M for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.